JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

Benzinga Newsdesk www.benzinga.com Negative 83.6%

Neg 83.6% Neu 0% Pos 0%

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.